Show simple item record

dc.contributor.author
Zouboulis, Viktor A.
dc.contributor.author
Zouboulis, Konstantin C.
dc.contributor.author
Zouboulis, Christos C.
dc.date.accessioned
2022-01-12T08:58:15Z
dc.date.available
2022-01-03T03:51:32Z
dc.date.available
2022-01-12T08:58:15Z
dc.date.issued
2022-01
dc.identifier.issn
1999-4923
dc.identifier.other
10.3390/pharmaceutics14010044
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/522613
dc.identifier.doi
10.3929/ethz-b-000522613
dc.description.abstract
Chronic inflammation and dysregulated epithelial differentiation, especially of hair follicle keratinocytes, have been suggested as the major pathogenetic pathways of hidradenitis suppura-tiva/acne inversa (HS). On the other hand, obesity and metabolic syndrome have additionally been considered as an important risk factor. With adalimumab, a drug has already been approved and numerous other compounds are in advanced-stage clinical studies. A systematic review was con-ducted to detect and corroborate HS pathogenetic mechanisms at the molecular level and identify HS molecular markers. The obtained data were used to confirm studied and off-label administered drugs and to identify additional compounds for drug repurposing. A robust, strongly associated group of HS biomarkers was detected. The triad of HS pathogenesis, namely upregulated inflammation, altered epithelial differentiation and dysregulated metabolism/hormone signaling was confirmed, the molecular association of HS with certain comorbid disorders, such as inflammatory bowel disease, arthritis, type I diabetes mellitus and lipids/atherosclerosis/adipogenesis was verified and common biomarkers were identified. The molecular suitability of compounds in clinical studies was confirmed and 31 potential HS repurposing drugs, among them 10 drugs already launched for other disorders, were detected. This systematic review provides evidence for the importance of molecular studies to advance the knowledge regarding pathogenesis, future treatment and biomarker-supported clinical course follow-up in HS.
en_US
dc.format
application/pdf
en_US
dc.language.iso
en
en_US
dc.publisher
MDPI
en_US
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
hidradenitis suppurativa
en_US
dc.subject
acne inversa
en_US
dc.subject
transcriptome
en_US
dc.subject
proteome
en_US
dc.subject
comorbid disorder
en_US
dc.subject
biomarker
en_US
dc.subject
drug repurposing
en_US
dc.subject
signaling pathway
en_US
dc.subject
druggable gene
en_US
dc.title
Hidradenitis suppurativa and comorbid disorder biomarkers, druggable genes, new drugs and drug repurposing—A molecular meta-analysis
en_US
dc.type
Review Article
dc.rights.license
Creative Commons Attribution 4.0 International
dc.date.published
2021-12-26
ethz.journal.title
Pharmaceutics
ethz.journal.volume
14
en_US
ethz.journal.issue
1
en_US
ethz.pages.start
44
en_US
ethz.size
22 p.
en_US
ethz.version.deposit
publishedVersion
en_US
ethz.identifier.wos
ethz.identifier.scopus
ethz.publication.place
Basel
en_US
ethz.publication.status
published
en_US
ethz.date.deposited
2022-01-03T03:51:43Z
ethz.source
SCOPUS
ethz.eth
yes
en_US
ethz.availability
Open access
en_US
ethz.rosetta.installDate
2022-01-12T08:58:22Z
ethz.rosetta.lastUpdated
2024-02-02T15:53:14Z
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=Hidradenitis%20suppurativa%20and%20comorbid%20disorder%20biomarkers,%20druggable%20genes,%20new%20drugs%20and%20drug%20repurposing%E2%80%94A%20molecular%20meta-analysis&rft.jtitle=Pharmaceutics&rft.date=2022-01&rft.volume=14&rft.issue=1&rft.spage=44&rft.issn=1999-4923&rft.au=Zouboulis,%20Viktor%20A.&Zouboulis,%20Konstantin%20C.&Zouboulis,%20Christos%20C.&rft.genre=article&rft_id=info:doi/10.3390/pharmaceutics14010044&
 Search print copy at ETH Library

Files in this item

Thumbnail

Publication type

Show simple item record